Concentrations of rhIFN-α2b in rabbit plasma and lymph

This is a raw data from the study of plasma and lymph pharmacokinetic profiles of recombinant human interferon alpha-2b (rhIFN-α2b), administered to rabbits by rectal and subcutaneous routes. Each animal received either Viferon® (Feron, Russia) in dosage form of rectal suppositories or Altevir® (PHARMAPARK LLC, Russia) in the dosage form of solution for injections. In both cases the administered dose of rhIFN-α2b was 1.0 mln IU/kg. Detection and quantification of rhIFN-α2b in plasma and lymph samples (n = 6 in each subgroup) were done using prevalidated sandwich ELISA. The range of analytical procedure was from 2 to 240 pg/ml (0.6-72.0 IU/ml). Data shows concentrations of rhIFN-α2b, measured in two matrices at different timepoints from 0 to 24 h after drug administration. Data codebook: time = time (hours) of blood or lymph collection after drug administration; drug = name of administered drug; matrix = matrix in which analyte concentration was measured; animal = number of rabbit in a subgroup; conc = concentration (IU/ml) of rhIFN-α2b. We found that plasma and lymph concentrations of rhIFN-α2b after s.c. administration were nearly the same at each sampling timepoint. However, after rectal administration the peak concentration of rhIFN-α2b was more than 13 times higher in lymph compared to plasma, with maximum lymph/plasma ratio 24.2 at 4 h after administration. Our results provide an evidence of selective lymphotropic transport of rhIFN-α2b after rectal administration. Rectal route of rhIFN-α2b delivery seems to be superior to s.c. route especially for the treatment of lymphatics-associated diseases, e.g. some viral infections and cancer.本数据集为重组人干扰素α-2b（recombinant human interferon alpha-2b，rhIFN-α2b）经直肠与皮下注射途径给予家兔后，其血浆与淋巴药代动力学特征研究的原始数据。每只家兔分别接受俄罗斯Feron公司生产的直肠栓剂剂型制剂Viferon®，或俄罗斯PHARMAPARK有限责任公司生产的注射用溶液剂Altevir®。两种给药方案中，重组人干扰素α-2b的给药剂量均为1.0百万国际单位/千克体重。采用预先验证的夹心酶联免疫吸附测定法（sandwich ELISA）对血浆与淋巴样本（每个亚组样本量n=6）中的重组人干扰素α-2b进行检测与定量分析。该分析方法的定量范围为2~240 pg/ml（0.6~72.0 IU/ml）。本数据集包含给药后0~24小时内不同时间点采集的两种生物基质样本中的重组人干扰素α-2b浓度数据。数据字典说明如下：time：给药后采集血液或淋巴样本的时间（小时）；drug：受试药物名称；matrix：检测分析物浓度所用的生物基质；animal：亚组内家兔编号；conc：重组人干扰素α-2b的浓度（IU/ml）。研究发现，皮下注射给药后，各采样时间点家兔血浆与淋巴中的重组人干扰素α-2b浓度基本一致。但直肠给药后，家兔淋巴中的重组人干扰素α-2b峰浓度较血浆高出13倍以上，给药后4小时时淋巴/血浆浓度比值达到最大值24.2。本研究结果证实，直肠给药后重组人干扰素α-2b存在选择性亲淋巴转运特性。相较于皮下注射途径，重组人干扰素α-2b的直肠给药途径更具优势，尤其适用于淋巴系统相关疾病的治疗，例如部分病毒性感染与恶性肿瘤。